Platelets, oxidant stress and erectile dysfunction: an hypothesis.
Jeremy
J Y
JY
Department of Cardiac Surgery, Division of Cardiac, Anaesthetic and Radiological Sciences, Bristol Royal Infirmary, Bristol, UK. j.y.jeremy@bristol.ac.uk
Angelini
G D
GD
Khan
M
M
Mikhailidis
D P
DP
Morgan
R J
RJ
Thompson
C S
CS
Bruckdorfer
K R
KR
Naseem
K M
KM
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D001792:Blood Platelets / Q000502:physiology*; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D011464:Epoprostenol / Q000378:metabolism; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008297:Male; D008954:Models, Biological; D009504:Neutrophils / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology*; D018384:Oxidative Stress; D010879:Piperazines / Q000627:therapeutic use; D010974:Platelet Aggregation; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D015106:3',5'-Cyclic-GMP Phosphodiesterases